CRISPR Therapeutics AG
CRSP63.990USD
+2.890+4.73%
收盤 10/31, 16:00（美東）報價延遲15分鐘
5.66B總市值
虧損本益比TTM
關於 CRISPR Therapeutics AG 公司
CRISPR Therapeutics AG 是一家總部位於瑞士的基因編輯公司，專注於開發基於 CRISPR/Cas9 的療法。CRISPR/Cas9 代表成簇的規律間隔短迴文重複序列 (CRISPR)/CRISPR 相關蛋白 9 (Cas9)，是一種基因編輯技術，即精確改變基因組 DNA 特定序列的過程。該公司旨在應用這項技術來破壞、刪除、糾正和插入基因，以治療基因定義的疾病並設計先進的細胞療法。該公司已獲得涵蓋 CRISPR/Cas9 和相關技術的知識產權 (IP) 的權利，並且還參與了自己的知識產權研究和其他許可工作。公司的產品開發和合作戰略旨在充分利用 CRISPR/Cas9 平臺的潛力，同時最大限度地提高成功開發其候選產品的可能性。
CRISPR Therapeutics AG簡介
公司代碼CRSP
公司名稱CRISPR Therapeutics AG
上市日期Oct 19, 2016
CEODr. Samarth Kulkarni, Ph.D.
員工數量393
證券類型Ordinary Share
年結日Oct 19
公司地址Baarerstrasse 14
城市ZUG
上市交易所NASDAQ Global Market Consolidated
國家Switzerland
郵編6300
電話41415613279
網址https://crisprtx.com/
公司代碼CRSP
上市日期Oct 19, 2016
CEODr. Samarth Kulkarni, Ph.D.
CRISPR Therapeutics AG公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
339.82K
+18.56%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Sandesh Mahatme
Mr. Sandesh Mahatme
Independent Director
Independent Director
--
--
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Fardis, Ph.D.
Dr. Maria Fardis, Ph.D.
Independent Director
Independent Director
--
--
Dr. H. Edward Fleming, Jr., M.D.
Dr. H. Edward Fleming, Jr., M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
339.82K
+18.56%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 10月26日 週日
更新時間: 10月26日 週日
持股股東
股東類型
持股股東
持股股東
佔比
ARK Investment Management LLC
11.20%
Capital International Investors
6.15%
BlackRock Institutional Trust Company, N.A.
5.96%
T. Rowe Price Investment Management, Inc.
4.05%
State Street Investment Management (US)
3.60%
其他
69.05%
持股股東
持股股東
佔比
ARK Investment Management LLC
11.20%
Capital International Investors
6.15%
BlackRock Institutional Trust Company, N.A.
5.96%
T. Rowe Price Investment Management, Inc.
4.05%
State Street Investment Management (US)
3.60%
其他
69.05%
股東類型
持股股東
佔比
Investment Advisor
46.56%
Investment Advisor/Hedge Fund
21.44%
Hedge Fund
3.78%
Venture Capital
3.45%
Research Firm
3.18%
Individual Investor
1.69%
Bank and Trust
1.57%
Pension Fund
0.46%
Sovereign Wealth Fund
0.45%
其他
17.43%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
966
73.70M
81.03%
+1.45M
2025Q2
949
75.06M
82.87%
+271.52K
2025Q1
952
68.11M
78.87%
-5.61M
2024Q4
955
68.20M
79.52%
-1.17M
2024Q3
962
64.14M
75.29%
-1.47M
2024Q2
976
63.22M
74.44%
-1.89M
2024Q1
986
62.72M
74.09%
+4.47M
2023Q4
985
55.14M
69.41%
-4.96M
2023Q3
992
55.19M
69.50%
-6.68M
2023Q2
1037
54.86M
69.51%
-8.28M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
ARK Investment Management LLC
10.18M
11.2%
+17.19K
+0.17%
Jun 30, 2025
Capital International Investors
5.59M
6.15%
-479.37K
-7.89%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.42M
5.96%
+3.00M
+124.40%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
3.68M
4.05%
-115.08K
-3.03%
Jun 30, 2025
State Street Investment Management (US)
3.27M
3.6%
+859.33K
+35.64%
Jun 30, 2025
Two Sigma Investments, LP
2.89M
3.18%
+904.31K
+45.53%
Jun 30, 2025
Orbis Investment Management Ltd.
2.76M
3.04%
+1.20M
+76.88%
Jun 30, 2025
UBS Financial Services, Inc.
2.59M
2.85%
+859.43K
+49.73%
Jun 30, 2025
Amova Asset Management Americas, Inc
2.41M
2.65%
-125.62K
-4.95%
Jun 30, 2025
The Vanguard Group, Inc.
2.28M
2.51%
+528.38K
+30.18%
Jun 30, 2025
查看更多
持股ETF
更新時間: 10月6日 週一
更新時間: 10月6日 週一
機構名稱
佔比
ARK Genomic Revolution ETF
9.22%
Global X Genomics & Biotechnology ETF
4.9%
ARK Innovation ETF
4.71%
AXS Green Alpha ETF
4.09%
WisdomTree BioRevolution Fund
2.74%
Virtus LifeSci Biotech Products ETF
2.09%
ROBO Global Healthcare Technology & Innovation ETF
2.01%
SPDR S&P Biotech ETF
1.44%
Direxion Daily S&P Biotech Bull 3X Shares
0.87%
Franklin Genomic Advancements ETF
0.77%
查看更多
ARK Genomic Revolution ETF
佔比9.22%
Global X Genomics & Biotechnology ETF
佔比4.9%
ARK Innovation ETF
佔比4.71%
AXS Green Alpha ETF
佔比4.09%
WisdomTree BioRevolution Fund
佔比2.74%
Virtus LifeSci Biotech Products ETF
佔比2.09%
ROBO Global Healthcare Technology & Innovation ETF
佔比2.01%
SPDR S&P Biotech ETF
佔比1.44%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.87%
Franklin Genomic Advancements ETF
佔比0.77%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
